Expression of the SARS-CoV-2 receptor-binding domain by live attenuated influenza vaccine virus as a strategy for designing a bivalent vaccine against COVID-19 and influenza.
Bivalent vaccine
COVID-19
Immunogenicity
Influenza
Recombinant influenza virus
SARS-CoV-2
Syrian hamsters
Virus vectored vaccine
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
09 Apr 2024
09 Apr 2024
Historique:
received:
09
01
2024
accepted:
22
03
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
8
4
2024
Statut:
epublish
Résumé
Influenza and SARS-CoV-2 are two major respiratory pathogens that cocirculate in humans and cause serious illness with the potential to exacerbate disease in the event of co-infection. To develop a bivalent vaccine, capable of protecting against both infections, we inserted the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein into hemagglutinin (HA) molecule or into the open reading frame of the truncated nonstructural protein 1 (NS1) of live attenuated influenza vaccine (LAIV) virus and assessed phenotypic characteristics of the rescued LAIV-RBD viruses, as well as their immunogenicity in mouse and Syrian hamster animal models. A panel of 9 recombinant LAIV-RBD viruses was rescued using the A/Leningrad/17 backbone. Notably, only two variants with RBD insertions into the HA molecule could express sufficient quantities of RBD protein in infected MDCK cells. Intranasal immunization of mice induced high levels of anti-influenza antibody responses in all chimeric LAIV-RBD viruses, which was comparable to the LAIV virus vector. The RBD-specific antibody responses were most pronounced in the variant expressing RBD194 fragment as a chimeric HA protein. This candidate was further tested in Syrian hamsters and was shown to be immunogenic and capable of protecting animals against both infections.
Identifiants
pubmed: 38589848
doi: 10.1186/s12985-024-02350-w
pii: 10.1186/s12985-024-02350-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
82Subventions
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Organisme : Russian Science Foundation
ID : 21-75-30003
Informations de copyright
© 2024. The Author(s).
Références
Yan X, Li K, Lei Z, Luo J, Wang Q, Wei S. Prevalence and associated outcomes of coinfection between SARS-CoV-2 and influenza: a systematic review and meta-analysis. Int J Infect Dis. 2023;136:29–36.
pubmed: 37648094
doi: 10.1016/j.ijid.2023.08.021
Wong A, Barrero Guevara LA, Goult E, Briga M, Kramer SC, Kovacevic A, et al. The interactions of SARS-CoV-2 with cocirculating pathogens: epidemiological implications and current knowledge gaps. PLoS Pathogens. 2023;19(3):e1011167.
pubmed: 36888684
pmcid: 9994710
doi: 10.1371/journal.ppat.1011167
Cao K, Wang X, Peng H, Ding L, Wang X, Hu Y, et al. A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice. J Virol. 2022;96(4):e0157821.
pubmed: 34908443
doi: 10.1128/jvi.01578-21
Ao Z, Ouyang MJ, Olukitibi TA, Warner B, Vendramelli R, Truong T, et al. A recombinant VSV-Based bivalent vaccine effectively protects against both SARS-CoV-2 and influenza a virus infection. J Virol. 2022;96(18):e0133722.
pubmed: 36069551
doi: 10.1128/jvi.01337-22
Bommireddy R, Stone S, Bhatnagar N, Kumari P, Munoz LE, Oh J, et al. Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses. Vaccines. 2022;10(6):944.
pubmed: 35746552
pmcid: 9230705
doi: 10.3390/vaccines10060944
Wang Z, Li Z, Shi W, Zhu D, Hu S, Dinh PC, et al. A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus. Sci Adv. 2023;9(25):eabo4100.
pubmed: 37352360
pmcid: 10289656
doi: 10.1126/sciadv.abo4100
Moderna. Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19. 2023.
Pfizer. Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19. 2023.
Chen J, Wang P, Yuan L, Zhang L, Zhang L, Zhao H, et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci Bullet. 2022.
Zhu F, Zhuang C, Chu K, Zhang L, Zhao H, Huang S, et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med. 2022.
Loes AN, Gentles LE, Greaney AJ, Crawford KHD, Bloom JD. Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice. Viruses. 2020;12(9):987.
pubmed: 32899480
pmcid: 7552029
doi: 10.3390/v12090987
Moser MJ, Hill-Batorski L, Bowen RA, Matejka SM, Marshall D, Kawaoka Y, et al. Intranasal single-replication influenza vector induces cross-reactive serum and mucosal antibodies against SARS-CoV-2 variants. Vaccines. 2023;11(6):1063.
pubmed: 37376452
pmcid: 10302585
doi: 10.3390/vaccines11061063
Zhao Y, Zhao L, Li Y, Liu Q, Deng L, Lu Y, et al. An influenza virus vector candidate vaccine stably expressing SARS-CoV-2 receptor-binding domain produces high and long-lasting neutralizing antibodies in mice. Veter Microbiol. 2022;271:109491.
doi: 10.1016/j.vetmic.2022.109491
Koonpaew S, Kaewborisuth C, Srisutthisamphan K, Wanitchang A, Thaweerattanasinp T, Saenboonrueng J, et al. A single-cycle influenza A virus-based SARS-CoV-2 vaccine elicits potent immune responses in a mouse model. Vaccines. 2021;9(8):850.
pubmed: 34451975
pmcid: 8402467
doi: 10.3390/vaccines9080850
Chaparian RR, Harding AT, Hamele CE, Riebe K, Karlsson A, Sempowski GD, et al. A virion-based combination vaccine protects against influenza and SARS-CoV-2 disease in mice. J Virol. 2022;96(15):e0068922.
pubmed: 35862698
doi: 10.1128/jvi.00689-22
Rudenko L, Yeolekar L, Kiseleva I, Isakova-Sivak I. Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: process challenges and success stories. Vaccine. 2016;34(45):5436–41.
pubmed: 27593158
pmcid: 5357706
doi: 10.1016/j.vaccine.2016.08.018
Prokopenko P, Matyushenko V, Rak A, Stepanova E, Chistyakova A, Goshina A, et al. Truncation of NS1 protein enhances T Cell-mediated cross-protection of a live attenuated influenza vaccine virus expressing wild-type nucleoprotein. Vaccines. 2023;11(3):501.
pubmed: 36992084
pmcid: 10056296
doi: 10.3390/vaccines11030501
Matyushenko V, Isakova-Sivak I, Kudryavtsev I, Goshina A, Chistyakova A, Stepanova E, et al. Detection of IFNgamma-Secreting CD4(+) and CD8(+) Memory T Cells in COVID-19 Convalescents after Stimulation of Peripheral Blood Mononuclear Cells with Live SARS-CoV-2. Viruses. 2021;13(8):1490.
pubmed: 34452355
pmcid: 8402842
doi: 10.3390/v13081490
Prokofyev A., Gershovich P., Strelkova A., Spirina N., Kondinskaya D., Yakovlev P., et al., inventorsAAV5-based vaccine for induction of specific immunity to SARS-CoV-2 virus and/or prevention of SARS-CoV-2-induced coronavirus infection. Patent RU 2761879 C1. 13.12.2021.
Kotomina T, Isakova-Sivak I, Stepanova E, Mezhenskaya D, Matyushenko V, Prokopenko P, et al. Neutralizing epitope of the fusion protein of respiratory syncytial virus embedded in the HA Molecule of LAIV virus is not sufficient to prevent RS virus pulmonary replication but ameliorates lung pathology following RSV infection in mice. Open Microbiol J. 2020;14:147–56.
doi: 10.2174/1874285802014010147
Isakova-Sivak I, Stepanova E, Matyushenko V, Niskanen S, Mezhenskaya D, Bazhenova E, et al. Development of a T cell-based COVID-19 vaccine using a live attenuated influenza vaccine viral vector. Vaccines. 2022;10(7):1142.
pubmed: 35891306
pmcid: 9318028
doi: 10.3390/vaccines10071142
Isakova-Sivak I, Matyushenko V, Stepanova E, Matushkina A, Kotomina T, Mezhenskaya D, et al. Recombinant live attenuated influenza vaccine viruses carrying conserved T-cell epitopes of human adenoviruses induce functional cytotoxic T-cell responses and protect mice against both infections. Vaccines. 2020;8(2):196.
pubmed: 32344618
pmcid: 7349758
doi: 10.3390/vaccines8020196
Hatta M, Kohlmeier CK, Hatta Y, Ozawa M, Kawaoka Y. Region required for protein expression from the stop-start pentanucleotide in the M gene of influenza B virus. J Virol. 2009;83(11):5939–42.
pubmed: 19279094
pmcid: 2681956
doi: 10.1128/JVI.00180-09
Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Epidemiol. 1938;27(3):493–7.
doi: 10.1093/oxfordjournals.aje.a118408
Kielkopf CL, Bauer W, Urbatsch IL. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins. Cold Spring Harbor protocols. 2021;2021(12):pdb-rot102228.
doi: 10.1101/pdb.prot102228
Mahmood T, Yang PC. Western blot: technique, theory, and trouble shooting. North Am J Med Sci. 2012;4(9):429–34.
doi: 10.4103/1947-2714.100998
Directive 2010/63/EU of the European Parliament 263 and of the Council 264 of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European Union. 2010;53:33–79.
Carroll T, Fox D, van Doremalen N, Ball E, Morris MK, Sotomayor-Gonzalez A, et al. The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters. PLoS Pathogens. 2022;18(2):e1009914.
pubmed: 35143587
pmcid: 8865701
doi: 10.1371/journal.ppat.1009914
Mezhenskaya D, Isakova-Sivak I, Kotomina T, Matyushenko V, Kim MC, Bhatnagar N, et al. A Strategy to elicit M2e-specific antibodies using a recombinant H7N9 live attenuated influenza vaccine expressing multiple M2e tandem repeats. Biomedicines. 2021;9(2):133.
pubmed: 33535408
pmcid: 7912525
doi: 10.3390/biomedicines9020133
Lee YN, Hwang HS, Kim MC, Lee YT, Lee JS, Moore ML, et al. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease. Antiviral Res. 2015;115:1–8.
pubmed: 25513755
doi: 10.1016/j.antiviral.2014.12.009
Smolonogina TA, Isakova-Sivak IN, Kotomina TS, Evsina AS, Stepanova EA, Prokopenko PI, et al. Generation of a vaccine against Group B streptococcal infection on the basis of a cold-adapted influenza A virus. Mol Genet Microbiol Virol. 2019;34(1):25–34.
doi: 10.3103/S0891416819010087
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–20.
pubmed: 32225176
doi: 10.1038/s41586-020-2180-5
Bayani F, SafaeiHashkavaei N, Uversky VN, Mozaffari-Jovin S, Sefidbakht Y. Insights into the structural peculiarities of the N-terminal and receptor binding domains of the spike protein from the SARS-CoV-2 Omicron variant. Comput Biol Med. 2022;147:105735.
pubmed: 35767919
pmcid: 9220253
doi: 10.1016/j.compbiomed.2022.105735
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12.
pubmed: 15264254
doi: 10.1002/jcc.20084
Kotomina T, Korenkov D, Matyushenko V, Prokopenko P, Rudenko L, Isakova-Sivak I. Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site. Human Vaccines Immunotherapeutics. 2018;14(12):2964–70.
pubmed: 30024831
pmcid: 6343631
doi: 10.1080/21645515.2018.1502529
DiPiazza A, Nogales A, Poulton N, Wilson PC, Martinez-Sobrido L, Sant AJ. Pandemic 2009 H1N1 Influenza Venus reporter virus reveals broad diversity of MHC class II-positive antigen-bearing cells following infection in vivo. Sci Rep. 2017;7(1):10857.
pubmed: 28883436
pmcid: 5589842
doi: 10.1038/s41598-017-11313-x
Jiang DB, Sun LJ, Cheng LF, Zhang JP, Xiao SB, Sun YJ, et al. Recombinant DNA vaccine of Hantavirus Gn and LAMP1 induced long-term immune protection in mice. Antiviral Res. 2017;138:32–9.
pubmed: 27923570
doi: 10.1016/j.antiviral.2016.12.001
Anwar A, Chandrasekaran A, Ng ML, Marques E, August JT. West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-associated membrane protein: increased cellular concentration of the transgene product, targeting to the MHC II compartment, and enhanced neutralizing antibody response. Virology. 2005;332(1):66–77.
pubmed: 15661141
doi: 10.1016/j.virol.2004.11.022
Lu Y, Raviprakash K, Leao IC, Chikhlikar PR, Ewing D, Anwar A, et al. Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies. Vaccine. 2003;21(17–18):2178–89.
pubmed: 12706709
doi: 10.1016/S0264-410X(03)00009-4
Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11(12):823–36.
pubmed: 22076556
doi: 10.1038/nri3084
Ye Q, Finn PW, Sweeney R, Bikoff EK, Riese RJ. MHC class II-associated invariant chain isoforms regulate pulmonary immune responses. J Immunol. 2003;170(3):1473–80.
pubmed: 12538710
doi: 10.4049/jimmunol.170.3.1473
Hung CF, Tsai YC, He L, Wu TC. DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther. 2007;15(6):1211–9.
pubmed: 17356542
doi: 10.1038/sj.mt.6300121
Kou Y, Xu Y, Zhao Z, Liu J, Wu Y, You Q, et al. Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis. Immunol Lett. 2017;190:51–7.
pubmed: 28728855
doi: 10.1016/j.imlet.2017.07.007
Luo M, Tao P, Li J, Zhou S, Guo D, Pan Z. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. J Virological Methods. 2008;154(1–2):121–7.
doi: 10.1016/j.jviromet.2008.08.011
Hanke T, Ondondo B, Abdul-Jawad S, Roshorm Y, Bridgeman A. Vector Delivery-Dependant Effect of Human Tissue Plasminogen Activator Signal Peptide on Vaccine Induction of T Cells. Journal of HIV and AIDS. 2016. https://ora.ox.ac.uk/objects/uuid:86b3a2ab-2c7d-403e-98ce-5717d5c97926 .
Premanand B, Zhong Wee P, Prabakaran M. Baculovirus surface display of immunogenic proteins for vaccine development. Viruses. 2018;10(6):298.
pubmed: 29857561
pmcid: 6024371
doi: 10.3390/v10060298
Reddy DA, Bergmann CC, Meyer JC, Berriman J, Both GW, Coupar BE, et al. Rotavirus VP6 modified for expression on the plasma membrane forms arrays and exhibits enhanced immunogenicity. Virology. 1992;189(2):423–34.
pubmed: 1322583
doi: 10.1016/0042-6822(92)90566-8
Yang DG, Chung YC, Lai YK, Lai CW, Liu HJ, Hu YC. Avian influenza virus hemagglutinin display on baculovirus envelope: cytoplasmic domain affects virus properties and vaccine potential. Mol Ther. 2007;15(5):989–96.
pubmed: 17375072
doi: 10.1038/mt.sj.6300131
Tanaka S, Saito K, Reed JC. Structure-function analysis of the Bcl-2 oncoprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival. J Biol Chem. 1993;268(15):10920–6.
pubmed: 8496157
doi: 10.1016/S0021-9258(18)82073-7
Kittel C, Ferko B, Kurz M, Voglauer R, Sereinig S, Romanova J, et al. Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J Virol. 2005;79(16):10672–7.
pubmed: 16051859
pmcid: 1182655
doi: 10.1128/JVI.79.16.10672-10677.2005
Bian C, Liu S, Liu N, Zhang G, Xing L, Song Y, et al. Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice. Antiviral Res. 2014;104:110–7.
pubmed: 24509239
doi: 10.1016/j.antiviral.2014.01.022
Zhang P, Gu H, Bian C, Liu N, Li Z, Duan Y, et al. Characterization of recombinant influenza A virus as a vector expressing respiratory syncytial virus fusion protein epitopes. J General Virol. 2014;95(Pt 9):1886–91.
doi: 10.1099/vir.0.064105-0
Manicassamy B, Manicassamy S, Belicha-Villanueva A, Pisanelli G, Pulendran B, Garcia-Sastre A. Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Nat Acad Sci United States America. 2010;107(25):11531–6.
doi: 10.1073/pnas.0914994107
Breen M, Nogales A, Baker SF, Perez DR, Martinez-Sobrido L. Replication-competent influenza A and B viruses expressing a fluorescent dynamic timer protein for in vitro and in vivo studies. PloS one. 2016;11(1):e0147723.
pubmed: 26809059
pmcid: 4725730
doi: 10.1371/journal.pone.0147723
Nogales A, Rodriguez-Sanchez I, Monte K, Lenschow DJ, Perez DR, Martinez-Sobrido L. Replication-competent fluorescent-expressing influenza B virus. Virus research. 2016;213:69–81.
pubmed: 26590325
doi: 10.1016/j.virusres.2015.11.014
Law JLM, Logan M, Joyce MA, Landi A, Hockman D, Crawford K, et al. SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. Vaccine. 2021;39(40):5769–79.
pubmed: 34481699
pmcid: 8387217
doi: 10.1016/j.vaccine.2021.08.081
Rahbar Z, Nazarian S, Dorostkar R, Sotoodehnejadnematalahi F, Amani J. Recombinant expression of SARS-CoV-2 receptor binding domain (RBD) in Escherichia coli and its immunogenicity in mice. Iranian J Basic Med Sci. 2022;25(9):1110–6.
Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586(7830):572–7.
pubmed: 32726802
doi: 10.1038/s41586-020-2599-8
Tai W, Zhang X, Drelich A, Shi J, Hsu JC, Luchsinger L, et al. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 2020;30(10):932–5.
pubmed: 32759966
doi: 10.1038/s41422-020-0387-5
Liu X, Drelich A, Li W, Chen C, Sun Z, Shi M, et al. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Vaccine. 2020;38(46):7205–12.
pubmed: 33010978
pmcid: 7508516
doi: 10.1016/j.vaccine.2020.09.058
Bertoletti A, Le Bert N, Qui M, Tan AT. SARS-CoV-2-specific T cells in infection and vaccination. Cell Mol Immunol. 2021;18(10):2307–12.
pubmed: 34471260
pmcid: 8408362
doi: 10.1038/s41423-021-00743-3
Rybkina K, Davis-Porada J, Farber DL. Tissue immunity to SARS-CoV-2: role in protection and immunopathology. Immunol Rev. 2022;309(1):25–39.
pubmed: 35752871
pmcid: 9339538
doi: 10.1111/imr.13112
Wang P, Zheng M, Lau SY, Chen P, Mok BW, Liu S, et al. Generation of DelNS1 influenza viruses: a strategy for optimizing live attenuated influenza vaccines. mBio. 2019;10(5):e02180-19.
pubmed: 31530680
pmcid: 6751066
doi: 10.1128/mBio.02180-19
Matyushenko V, Kotomina T, Kudryavtsev I, Mezhenskaya D, Prokopenko P, Matushkina A, et al. Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell responses. Antiviral Res. 2020;182:104864.
pubmed: 32585323
pmcid: 7313889
doi: 10.1016/j.antiviral.2020.104864
Vasilyev K, Shurygina AP, Sergeeva M, Stukova M, Egorov A. Intranasal immunization with the influenza A virus encoding truncated NS1 protein protects mice from heterologous challenge by restraining the inflammatory response in the lungs. Microorganisms. 2021;9(4):690.
pubmed: 33810549
pmcid: 8067201
doi: 10.3390/microorganisms9040690
Pulkina A, Vasilyev K, Muzhikyan A, Sergeeva M, Romanovskaya-Romanko E, Shurygina AP, et al. IgGkappa signal peptide enhances the efficacy of an influenza vector vaccine against respiratory syncytial virus infection in mice. Int J Mol Sci. 2023;24(14):11445.
pubmed: 37511205
pmcid: 10380829
doi: 10.3390/ijms241411445
Sridhar S, Brokstad KA, Cox RJ. Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines. Vaccines. 2015;3(2):373–89.
pubmed: 26343192
pmcid: 4494344
doi: 10.3390/vaccines3020373